{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:14:54Z","timestamp":1760296494735},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7176,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1023\/a:1008344528791","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"613-616","source":"Crossref","is-referenced-by-count":7,"title":["A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Pignata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Varriale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Casella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Iodice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tramontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ricchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"DeVivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vernaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tramontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008344528791_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with placlitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1023\/A:1008344528791_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0923-7534(20)31491-5","article-title":"Advanced epithelial ovarian cancer: 1998 consensus statements","volume":"10","author":"Berek","year":"1999","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1023\/A:1008344528791_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0923-7534(20)31484-8","article-title":"Gemcitabine in the treatment of ovarian cancer","volume":"10","author":"Hansen","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008344528791_bb0020","first-page":"1379","article-title":"Gemcitabine","volume":"18","author":"Hansen","year":"1999","journal-title":"carbo-platin, and paclitaxel as first-line treatment of ovarian cancer FIGO Stage IIB-IV. Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008344528791_bb0025","first-page":"45","article-title":"Hansen H","volume":"19","author":"Lund","year":"1993","journal-title":"Clinical and preclinical activity of 2\u2019.2\u2019-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev"},{"key":"10.1023\/A:1008344528791_bb0030","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/86.20.1530","article-title":"Phase II study of gemcitabine in previously treated ovarian cancer patients","volume":"86","author":"Lund","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008344528791_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity og gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and placlitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1008344528791_bb0040","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008344528791_bb0045","first-page":"4109","article-title":"Inhibition of human ovarian cancer colony formation by adriamicin and its metabolites","volume":"40","author":"Ozols","year":"1980","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008344528791_bb0050","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.1991.9.9.1668","article-title":"Cyclophosphamide plus cisplatin versus clophoshamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis","volume":"9","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008344528791_bb0055","series-title":"Advances in Anthracycline Chemotherapy","first-page":"91","article-title":"A phase II study of epirubicin in advanced ovarian carcinoma","author":"Trop\u00e8","year":"1984"},{"key":"10.1023\/A:1008344528791_bb0060","first-page":"433","article-title":"High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: The EORTC-GCCG experience","volume":"14","author":"Vermoken","year":"1995","journal-title":"Eur J Gynecol Oncol"},{"key":"10.1023\/A:1008344528791_bb0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000011977","article-title":"A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer","volume":"56","author":"Lauria","year":"1999","journal-title":"Oncology"},{"key":"10.1023\/A:1008344528791_bb0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1097-0215(19990129)80:3<413::AID-IJC13>3.0.CO;2-I","article-title":"Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines","volume":"80","author":"Zoli","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1023\/A:1008344528791_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1006121608414","article-title":"Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: Results of a phase I study","volume":"16","author":"Luftner","year":"1998","journal-title":"Invest New Drugs"},{"key":"10.1023\/A:1008344528791_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1023\/A:1008344528791_bb0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"10","key":"10.1023\/A:1008344528791_bb0090","first-page":"72","article-title":"Gemcitabine in cisplatin-resistant ovarian cancer","volume":"23","author":"Lund","year":"1996","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1023\/A:1008344528791_bb0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0959-8049(96)00338-3","article-title":"Gemcitabine in ovarian cancer An overview of safety and efficacy","volume":"33","author":"Kaufmann","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008344528791_bb0100","first-page":"17","article-title":"High-dose intensity regimens with epirubicin in ovarian cancer","volume":"21","author":"Vermoken","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008344528791_bb0105","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/5\/613\/19478292\/11-5-613.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:16:04Z","timestamp":1582182964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419550694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["S0923753419550694"],"URL":"https:\/\/doi.org\/10.1023\/a:1008344528791","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}